We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Long-Term Breast Cancer Outcomes of Pregnancy-Associated Breast Cancer (PABC) in a Prospective Cohort.
- Authors
Jo, Hyunji; Park, Seri; Kim, Hye Ryeon; Kim, Hongsik; Hong, Joohyun; Lee, Jeong Eon; Yu, Jonghan; Chae, Byung Joo; Lee, Se Kyung; Ryu, Jai Min; Oh, Soo-young; Choi, Suk Joo; Kim, Ji-Yeon; Ahn, Jin Seok; Im, Young-Hyuck; Nam, Eun Mi; Nam, Seok Jin; Park, Yeon Hee
- Abstract
Simple Summary: This study explored the characteristics, treatment, and survival outcomes of patients with pregnancy-associated breast cancer (PABC) in Korea. All patients of this study received standard treatments according to the National Comprehensive Cancer Network guideline. Compared to the non-PABC group, the PABC group had a lower percentage of hormone receptor positivity, increased HER2 overexpression, and higher Ki-67 levels. No maternal complications were observed in patients with PABC. In addition, the 5-year disease-free survival and overall survival rates were significantly poorer in the PABC group than in the non-PABC group. After adjusting for tumor characteristics, PABC was still associated with poor prognosis. This is the first report of the PABC population from a prospective cohort. Exploration to elucidate biologic relevance will follow. Background: Given that peak age of breast cancer (BC) is younger in Asians than in Western populations, relatively higher prevalence of pregnancy-associated breast cancer (PABC) has been reported. This study aimed to analyze the characteristics and clinical outcomes of PABC in Korea. Methods: We defined PABC as BC diagnosed during pregnancy or in the first postpartum year. We compared the clinicopathological characteristics and BC outcomes between patients with PABC and non-PABC patients in the prospective YBC cohort from Samsung Medical Center. Results: In total, 1492 patients were initially enrolled, and 1364 patients were included, of which 93 had PABC (6.8%). The median age of patients with PABC was 34 years. Hormone receptor expression was lower (64.6% vs 74.6%) and frequency of HER2 overexpression was higher (26.9% vs 17.6%) in patients with PABC than in non-PABC patients. The 5-year overall survival (OS) rates were 83.2% and 93.4% in patients with PABC and non-PABC patients, respectively (p < 0.001). The 5-year disease-free survival (DFS) rates were 72.2% and 83.8% in PABC and non-PABC patients. Conclusion: Compared to non-PABC patients, patients with PABC had poorer OS and DFS in this prospective cohort. Exploratory biomarker analysis for PABC is warranted.
- Subjects
SOUTH Korea; BREAST cancer prognosis; BREAST tumor treatment; CANCER prognosis; CANCER treatment; ACADEMIC medical centers; ONCOGENES; CELL receptors; TREATMENT effectiveness; CANCER; COMPARATIVE studies; CANCER patients; GENE expression; PREGNANCY outcomes; PREGNANCY complications; SYMPTOMS; DESCRIPTIVE statistics; TUMOR markers; PROGRESSION-free survival; BREAST tumors; LONGITUDINAL method; HORMONE receptor positive breast cancer; EVALUATION; PREGNANCY
- Publication
Cancers, 2022, Vol 14, Issue 19, p4839
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers14194839